CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut

IPO/OfferingPositive
AI Analysis

Summary

City Therapeutics, an RNAi startup founded by former Alnylam executives, is targeting a $158M IPO, planning to sell 9.72 million shares at $17 per share. Iambic is also pursuing a Nasdaq debut with a $135M offering.

Importance:5/10
Sentiment:
0.30
IPORNAiCapital_RaiseBiotech
Related Companies

Read the original article

Published by Endpoints News on October 9, 2026 2:15 PM

Read Original